These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 33562401)
1. The Ins and Outs of RAS Effector Complexes. Kiel C; Matallanas D; Kolch W Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33562401 [TBL] [Abstract][Full Text] [Related]
2. RAS mutations in human cancers: Roles in precision medicine. Murugan AK; Grieco M; Tsuchida N Semin Cancer Biol; 2019 Dec; 59():23-35. PubMed ID: 31255772 [TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Baker NM; Yee Chow H; Chernoff J; Der CJ Clin Cancer Res; 2014 Sep; 20(18):4740-6. PubMed ID: 25225063 [TBL] [Abstract][Full Text] [Related]
4. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? Lv J; Wang J; Chang S; Liu M; Pang X Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443 [TBL] [Abstract][Full Text] [Related]
5. RAS-mediated oncogenic signaling pathways in human malignancies. Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560 [TBL] [Abstract][Full Text] [Related]
6. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Fang B Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096 [TBL] [Abstract][Full Text] [Related]
7. Targeting the RAS-dependent chemoresistance: The Warburg connection. Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Ras for cancer treatment: the search continues. Baines AT; Xu D; Der CJ Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085 [TBL] [Abstract][Full Text] [Related]
13. The Importance of Being PI3K in the RAS Signaling Network. Cuesta C; Arévalo-Alameda C; Castellano E Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356110 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Haigis KM; Kendall KR; Wang Y; Cheung A; Haigis MC; Glickman JN; Niwa-Kawakita M; Sweet-Cordero A; Sebolt-Leopold J; Shannon KM; Settleman J; Giovannini M; Jacks T Nat Genet; 2008 May; 40(5):600-8. PubMed ID: 18372904 [TBL] [Abstract][Full Text] [Related]
15. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Erickson KE; Rukhlenko OS; Posner RG; Hlavacek WS; Kholodenko BN Semin Cancer Biol; 2019 Feb; 54():162-173. PubMed ID: 29518522 [TBL] [Abstract][Full Text] [Related]
16. A model for RAS mutation patterns in cancers: finding the sweet spot. Li S; Balmain A; Counter CM Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765 [TBL] [Abstract][Full Text] [Related]
17. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Downward J Clin Cancer Res; 2015 Apr; 21(8):1802-9. PubMed ID: 25878361 [TBL] [Abstract][Full Text] [Related]
18. The role of RAS oncogenes in controlling epithelial mechanics. Nyga A; Ganguli S; Matthews HK; Baum B Trends Cell Biol; 2023 Jan; 33(1):60-69. PubMed ID: 36175301 [TBL] [Abstract][Full Text] [Related]
19. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present). Sacco E; Spinelli M; Vanoni M Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088 [TBL] [Abstract][Full Text] [Related]
20. Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. Burge RA; Hobbs GA Adv Cancer Res; 2022; 153():29-61. PubMed ID: 35101234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]